Promoting Tolerance to Common Allergens in High-Risk Children: Global Prevention of Asthma in Children (GPAC) Study

PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions
AsthmaAllergic Sensitization
Interventions
BIOLOGICAL

Oral mucosal immunoprophylaxis (OMIP)

OMIP consists of a mixture of allergen extracts including 0.2 milliliters (mL) timothy grass, 0.2 mL cat, and 0.2 mL house dust mite for a total daily dose of 0.6 mL.

BIOLOGICAL

Placebo

The placebo consists of three 0.2 mL vials of solution mixed together for a total daily dose of 0.6 mL.

Trial Locations (3)

3052

Royal Children's Hospital, Melbourne

6008

Telethon Institute for Child Health Research, Perth

10029

Mount Sinai School of Medicine, New York

All Listed Sponsors
collaborator

Immune Tolerance Network (ITN)

NETWORK

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00346398 - Promoting Tolerance to Common Allergens in High-Risk Children: Global Prevention of Asthma in Children (GPAC) Study | Biotech Hunter | Biotech Hunter